Fri, Oct 31, 2014, 4:49 AM EDT - U.S. Markets open in 4 hrs 41 mins


% | $
Quotes you view appear here for quick access.


  • biohitechinvestor biohitechinvestor Jan 3, 2013 1:07 PM Flag

    Potential here is billions....

    If clinical results are positive we have a company that will get to a value of $2-5 billion in a short period of time and then who knows the limits here? Sit and wait and if the trials are a bust, you lose everything you invested. You only invest in this company money you can lose...completely lose. All the best for a great 2013...we'll know by the end of the year if the company becomes a monster or just fades away into the sunset...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • hehehehe

    • Just AMD potential has been estimated between 28 - 30 Billion market. SMD market? Blood market?

      Sentiment: Strong Buy

      • 1 Reply to kevswede
      • For me it's never about hyped, estimated, or true market potential. You or I will never know accurate numbers. Instead, pro bio-tech investors care about things like this:

        1. How many different trials/studies are ongoing, in the same and OTHER fields, for the the disease. Note STEM is now authorized for amd/smd using stem cells, and there are a dozen other trials and studies to treat amd/smd that are non-cell based.

        2. How long on average before conclusive results are seen (e.g. phase III indicators).

        3. How long on average, do trials take (10-15 years, sometimes expedited to 5-10 yrs). In this regard, and before the hypsters begin about orhan status, etc....remember, hEsc is a political hotcake.....the FDA is just as likely to take longer to review and approve, because they can't afford to make ANY mistakes, lest the far right will have their field day, should anything subsequently go wrong in the therapy or application.

        4. How competent management, and what is the likelihood of additional dilution? We all know the answer to this one.

        At the end of the day, for the deep pockets to invest here, it's not about market potential 5-10 yrs away, it's about how great is the risk, and long many years sitting on that risk. This is why someone George Soros, or the Bill Gates Foundation hasn't invested a dime in actc (or, for the same reason, why Lanza or Rabin have not invested a dime in ACTC). Normally, these guys would financially support new and progressive science, as we know the Dems in general do. One might argue, ACTC's IND for amd and smd might never have been approved by the FDA were it not for the Obama's election (and that's not a criticisim of the party, or ACTC). Maybe what the pros know better than longs here is this: there is such a thing as investing too early, in promising science. Too easy to lose everything through constant dilution, and even easier to lose it all if just a few insiders decide to sell (e.g. the Caldwell estate), or something goes wrong with one of the patients. These are just a few reasons why actc is a penny stock that can't support six cents.

7.03+0.01(+0.13%)Oct 30 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Groupon, Inc.
NasdaqGSThu, Oct 30, 2014 4:00 PM EDT
Flextronics International Ltd.
NasdaqGSThu, Oct 30, 2014 4:00 PM EDT